Vertex Pharmaceuticals: RAINIER Data Strengthen Best-in-Class IgAN Potential and Support Upside Beyond Durable CF Cash Flows

BMO Capital analyst Evan Seigerman maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $600.00.

Evan Seigerman has given his Buy rating due to a combination of factors that underscore Vertex’s strengthening growth outlook. He highlights the interim RAINIER results, where povetacicept showed nearly a 50% placebo‑adjusted reduction in proteinuria in IgA nephropathy, a level of efficacy that aligns with his prior bullish expectations and compares favorably versus emerging competitors, suggesting best‑in‑class potential.

He also notes that safety findings support a clean risk‑benefit profile, with overall adverse and serious adverse events comparable to or better than placebo, which should smooth the path to a timely BLA filing and a potential 2H26 launch. In addition, Seigerman emphasizes that cystic fibrosis remains a core, durable cash generator that funds Vertex’s expanding pipeline, and that recent positive developments with assets like VX‑548 and VX‑147 further justify his view that there is still upside in the shares, reinforcing his Outperform recommendation.

In another report released today, Citi also maintained a Buy rating on the stock with a $585.00 price target.